Non-Thyroidal Illness Syndrome (NTIS)

(also called Euthyroid Sick Syndrome or Low T3 Syndrome)


Definition

Non-thyroidal illness syndrome (NTIS) is a state of altered thyroid hormone metabolism, regulation, transport, and action occurring during systemic illness, without intrinsic thyroid gland pathology.

Thyroid gland structurally normal
Abnormal TFTs reflect adaptive + maladaptive responses
Common in ICU and critically ill patients


Terminology 

Term

Meaning

Euthyroid Sick Syndrome

Old umbrella term

Low T3 syndrome

Early/mild NTIS

Low T3–T4 syndrome

Severe/prolonged NTIS

Consumptive hypothyroidism

Rare extreme ( D3 in tumors, hemangiomas)


Typical Hormonal Pattern

Parameter

Change

Mechanism

Total T3

↓↓↓

D1, D3

Free T3

↓↓↓

Reduced conversion + transport

Reverse T3 (rT3)

↑↑

Reduced clearance

Total T4

Normal

Severe illness

Free T4

Normal /

Binding changes

TSH

Normal /

Hypothalamic suppression

 Low T3 + high rT3 = hallmark biochemical signature


Pathophysiology 

 1️⃣ Deiodinase Dysfunction 

Enzyme

Change

Effect

Type 1 (D1)

T4 T3

Type 2 (D2)

intracellular T3

Type 3 (D3)

T4 rT3 (inactive)

 Central mechanism of NTIS

 2️⃣ Cytokine-Mediated Endocrine Suppression

Inflammatory cytokines:

  • IL-1
  • IL-6
  • TNF-α
  • IFN-γ

Effects:

  • Hypothalamic TRH
  • Pituitary TSH secretion & pulsatility
  • Thyroid hormone receptor expression

 Explains normal or low TSH despite low T3/T4


 3️⃣ Altered Thyroid Hormone Binding

  • Thyroxine Binding Globulin (TBG)
  • Albumin
  • Non-esterified fatty acids
  • Drug displacement

Result:

  • Total hormone levels misleading
  • Free hormone assays may also be unreliable in ICU


 4️⃣ Impaired Cellular Uptake

  • MCT8 & OATP1C1 transporters
  • Reduced intracellular T3 despite normal serum levels

 Leads to tissue-level hypothyroidism


 5️⃣ Thyroid Hormone Resistance at Nuclear Level

  • Thyroid hormone receptor (TRα, TRβ)
  • Altered co-activator / co-repressor balance
  • Reduced transcription of T3-dependent genes


 6️⃣ Hypothalamic–Pituitary–Adrenal (HPA) Axis Interaction

  • Cortisol suppresses:
    • TRH
    • TSH
    • Peripheral T4 T3 conversion

 Explains overlap with critical illness–related corticosteroid insufficiency


Why Does NTIS Occur? (Adaptive vs Maladaptive)

 Early / Acute Phase (Adaptive)

  • Basal metabolic rate
  • Oxygen consumption
  • Protein catabolism
  • Energy conservation during stress

 Prolonged ICU / Chronic Critical Illness (Maladaptive)

  • Muscle wasting
  • Impaired wound healing
  • Immunosuppression
  • Myocardial dysfunction
  • Poor neurological recovery

Clinical Settings Associated with NTIS

🔸 Acute Critical Illness

  • Sepsis / septic shock
  • ARDS
  • Polytrauma
  • Burns
  • Acute MI
  • Stroke / TBI
  • Post-cardiac surgery
  • Major abdominal surgery

🔸 Chronic Systemic Illness

  • CKD (especially dialysis)
  • Cirrhosis
  • Advanced heart failure
  • Malignancy
  • Starvation / anorexia nervosa
  • Prolonged ICU stay (>7–10 days)


Drug-Induced NTIS 

Drug

Mechanism

Dopamine

TSH secretion

Glucocorticoids

TRH, TSH, T4T3

Amiodarone

Deiodinase, iodine load

Propranolol

Peripheral conversion

Iodinated contrast

Deiodinase

Heparin

Free T4 artefact


Severity-Based Biochemical Progression

Stage

TFT Pattern

Prognosis

Mild illness

T3

Good

Moderate illness

T3 + rT3

Variable

Severe illness

T3 + T4

Poor

Prolonged ICU

T3 + T4 + TSH

High mortality

 Low T4 is the strongest mortality predictor


NTIS vs True Hypothyroidism 

Feature

NTIS

Hypothyroidism

T3

T4

Normal /

TSH

Normal /

rT3

Goitre

#

Possible

Antibodies

#

Often +

Treatment

 No

 Yes


Recovery Phase – IMPORTANT PITFALL

  • TSH may transiently rise (5–20 mIU/L)
  • Mimics subclinical hypothyroidism
  • Do NOT treat
  • Recheck after 6–8 weeks


NTIS in ICU – Practical Interpretation

Abnormal TFTs common (up to 70% ICU patients)
TFTs do NOT guide therapy
Measure TFTs only if thyroid disease suspected


Should NTIS Be Treated? (LATEST GUIDELINE CONSENSUS)

Routine Thyroid Hormone Therapy – NOT Recommended

  • No mortality benefit
  • No ICU outcome improvement
  • Risks:
    • Arrhythmias
    • Increased myocardial oxygen demand
    • Catabolism

 Experimental settings only:

  • Prolonged ICU (>2–3 weeks)
  • Research protocols
  • Selected pediatric congenital heart disease studies

📌 Standard of care = Treat underlying illness only


Prognostic Significance

  • T3 correlates with:
    • SOFA score
    • APACHE II
    • ICU mortality
  • NTIS = marker of disease severity


When to Investigate for True Thyroid Disease in ICU

Past thyroid disease
Goitre / ophthalmopathy
TSH >10 mIU/L
TSH <0.01 mIU/L
Persistent abnormal TFTs after recovery